Zenyaku Kogyo Co., Ltd. and Chugai Pharmaceutical Co., Ltd. have announced obtaining approval from Japan's Ministry of Health, Labour and Welfare to commercially distribute Rituxan®.

Mineralys Therapeutics Reports Initial Participant Receives Dose in Start-HTN, Their Second Major Study of Lorundrostat Aimed at Hypertension Management.

Jazz Pharmaceuticals plc announced early results from its Phase 2 trial evaluating the efficacy and safety of JZP150, a selective FAAH enzyme inhibitor, in adults with PTSD.

The FDA has sanctioned an update to the packaging of Kite Pharma's Yescarta® treatment, now incorporating information on patient survival rates.

WAINUA™ (eplontersen) Receives Groundbreaking US Sanction as a Treatment for Polyneuropathy in Adult Hereditary Transthyretin Amyloidosis Cases.

Sanofi has terminated its study of tusamitamab ravtansine due to a Phase 3 trial in second-line NSCLC failing to achieve its main goal.

GSK plc has entered an exclusive partnership with Hansoh Pharma to co-develop and market HS-20093, an antibody-drug conjugate (ADC) targeting B7-H3 with a clinically proven topoisomerase inhibitor payload for serious medical conditions.

Aurinia Pharmaceuticals Inc. announced it filed an IND application for AUR200 with the FDA to advance its development.

Merck announced it got an FDA Complete Response Letter regarding its New Drug Application for gefapixant.

Rallybio Corporation revealed early Phase 1 trial results for RLYB116, a novel drug with prolonged action and subcutaneous administration in low volumes.

Almirall S.A. has recently launched a phase I clinical trial to assess the safety profile, pharmacokinetic properties, immunogenic potential, and pharmacodynamic effects of ALM223.

Tiziana Life Sciences Ltd. has announced the start of a Phase 2a trial, assessing the efficacy and safety of two doses of intranasal foralumab compared to placebo in patients with non-active secondary-progressive multiple sclerosis.